Has Inflammation a Significant Implication in Lung Cancer Evolution?

• Register: ClinicalTrials.gov
• Last refreshed on: 30 August 2021
• Main ID: NCT02484872
• Date of registration: 24/06/2015
• Prospective Registration: No
• Primary sponsor: European Lung Cancer Working Party
• Public title: Has Inflammation a Significant Implication in Lung Cancer Evolution?
• Scientific title: L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?
• Date of first enrolment: May 2015
• Target sample size: 400
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT02484872
• Study type: Observational

Countries of recruitment

Belgium

Contacts

• Name: Anne-Pascale Meert, MD, PhD
• Affiliation: Jules Bordet Institute

Key inclusion & exclusion criteria

Inclusion Criteria:

- Lung neoplasms irrespective of stage, histology

Exclusion Criteria:

- Previously treated lung neoplasms

- A history of prior malignant tumour, except non-melanoma skin cancer or in situ
carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free
interval)



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Lung Neoplasms

Primary Outcome(s)

Survival [Time Frame: Measured from diagnosis until death or last date known to be alive, or at least 48 months]

Secondary Outcome(s)

Complications leading to emergency/ICU [Time Frame: From inclusion until death, or a least 48 months]

Secondary ID(s)

ELCWP01501

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Jules Bordet Institute